Pfizer (NYSE: PFE | PFE Price Prediction) is one of the most widely held dividend stocks among retirement investors. The stock currently yields 6.3%, well above most fixed-income alternatives. But a high yield can be a warning sign, and right now Pfizer’s payout mechanics deserve a hard look.
Dividend Snapshot
| Metric | Value |
|---|---|
| Annual Dividend | $1.72/share |
| Dividend Yield | 6.3% |
| Quarterly Dividend | $0.43/share |
| Consecutive Years of Increases | 16 years (2010–2026) |
| Most Recent Increase | $0.42 to $0.43 (2025) |
| Dividend Aristocrat Status | No (cut in 2009) |
The Payout Ratio Has Crossed a Critical Threshold
Pfizer paid $9.771 billion in dividends in FY2025 against free cash flow of just $9.076 billion, meaning the dividend exceeded free cash flow by $695 million. When a company pays out more than it generates in free cash, it must draw on reserves or borrow to fund the dividend, an unsustainable practice if it persists.
| Metric | Value | Assessment |
|---|---|---|
| Earnings Payout Ratio (Adjusted EPS) | $1.72 / $3.22 = 53.4% | Healthy |
| Earnings Payout Ratio (GAAP TTM EPS) | $1.72 / $1.36 = 126.5% | Concerning |
| FCF Payout Ratio | $9.771B / $9.076B = 107.7% | Red Flag |
| Operating CF Coverage | $11.705B OCF / $9.771B dividends = 1.20x | Weak |
The adjusted EPS payout ratio of 53% looks manageable, but adjusted figures exclude real costs. On a GAAP basis, TTM diluted EPS is $1.36 against a $1.72 annual dividend, putting the GAAP payout ratio above 100%. This gap is largely driven by $4.4 billion in non-cash impairment charges in Q4 2025. In 2023, the dividend exceeded FCF by $4.454 billion, a far more severe shortfall.
Debt Is Elevated and Liquidity Has Shrunk
| Metric | Value | Assessment |
|---|---|---|
| Total Debt | $67.4 billion | Elevated |
| Debt-to-Equity | 0.78x | Moderate |
| Cash on Hand | $1.14 billion | Thin |
| Total Liquid Assets | $13.6 billion | Declining |
Total debt rose from $63.6 billion in 2024 to $67.4 billion in 2025, while liquid assets fell from $20.5 billion to $13.6 billion. The debt load reflects Pfizer’s acquisition strategy, including the Seagen oncology deal. The balance sheet is tighter today than during the COVID-era windfall years.
Sixteen Years of Increases, but the 2009 Cut Still Matters
| Year | Quarterly Dividend | Change |
|---|---|---|
| 2025-2026 | $0.43 | +2.4% |
| 2024 | $0.42 | +2.4% |
| 2023 | $0.41 | +2.5% |
| 2022 | $0.40 | +2.6% |
| 2021 | $0.39 | +2.6% |
Pfizer has raised its dividend every year since 2010, but growth is modest at roughly 2% to 3% annually. Pfizer cut its dividend in half in 2009, from $0.32 to $0.16 per quarter, during the financial crisis, confirming management will act if pressure becomes severe enough.
Management Signals Stability, but the Focus Is on Growth
CEO Albert Bourla said on the Q4 2025 earnings call: “With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer’s foundation for future growth.” The emphasis on pipeline catalysts over explicit dividend commitments is notable. Pfizer is expected to post Q1 2026 earnings on May 5, and that call will be the next meaningful signal on capital allocation. Positively, no share repurchases are planned in 2026, which preserves cash for the dividend.
Safe for Now, but the Margin Has Narrowed Significantly
Dividend Safety Rating: Moderate Risk
Pfizer’s 2026 guidance calls for adjusted EPS of $2.80 to $3.00, which would keep the adjusted payout ratio below 65%. But free cash flow recovery is the real test. In 2024, FCF of $9.835 billion covered the $9.512 billion dividend, suggesting the 2025 shortfall may be temporary. The non-COVID portfolio grew 6% for the full year, and the Seagen pipeline adds long-term optionality.
For retirement investors already holding Pfizer, the dividend appears sustainable near term, provided FCF stabilizes. The May 5 earnings call is the next critical checkpoint. For investors considering adding new money purely for the 6.3% yield, the payout ratio risk is real. If free cash flow recovers and the non-COVID portfolio keeps growing, the dividend holds. If COVID revenues decline faster than expected or the Metsera acquisition strains cash further, the cushion thins.
Top Gaining Stocks
Top Losing Stocks